Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02323737

Phase II Study of Irinotecan and Cisplatin in Extensive-stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer Clinical Trial

Official title:
Cisplatin Combined With Irinotecan or Etoposide for Untreated Extensive-stage Small Cell Lung Cancer: a Multicenter Randomized Control Clinical Trial

Clinical Trial Summary

Patients with untreated extensive-stage small cell lung cancer(SCLC) were randomly assigned to receive either irinotecan/cisplatin (IP) or etoposide/cisplatin(EP), The association of efficacy and toxicity of IP regimen was analyzed.

Clinical Trial Description

This is a randomized, multicenter study. Patients are randomized to irinotecan/cisplatin (IP) or etoposide/cisplatin (EP) treatment arms. The IP regimen consisted of at most 6 cycles of irinotecan 65 mg/m2 of body-surface area on days 1, 8 and cisplatin 75mg/m2 of body-surface area on day 1. The EP regimen consisted of at most 6 cycles of etoposide 100 mg/m2 of body-surface area from day 1 to 3 and cisplatin 75mg/m2 of body-surface area on day 1. Cycle length for the two arms was 3 weeks. The dose adjustment was allowed in at most within ±5% per investigator discretion if necessary. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02323737
Study type Interventional
Source Chinese Academy of Medical Sciences
Contact
Status Completed
Phase Phase 2
Start date July 2010
Completion date June 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05509699 - Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT05975944 - Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung Cancer Phase 1/Phase 2
Not yet recruiting NCT04562337 - A Phase II Clinical Study of SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in Extensive Small Cell Lung Cancer Phase 2
Completed NCT00616109 - Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC Phase 2
Active, not recruiting NCT04373369 - Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04254471 - This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients Phase 2/Phase 3
Active, not recruiting NCT04774380 - Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer Phase 3
Active, not recruiting NCT01555710 - Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study) Phase 3
Completed NCT00682981 - A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC) Phase 1/Phase 2
Recruiting NCT04397003 - Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04702880 - A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer Phase 2
Active, not recruiting NCT04487756 - Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer Phase 1/Phase 2
Recruiting NCT03135977 - Apatinib and Etoposide as the Maintenance Therapy in Extensive-stage Small Cell Lung Cancer After First-line Chemotherapy Phase 2
Completed NCT03913455 - Guadecitabine in Combination With Carboplatin in Extensive Stage Small Cell Lung Cancer Phase 2
Recruiting NCT04663438 - Real World Study of Efficacy and Safety of Atezolizumab Plus Chemotherapy in Chinese Patients With ES-SCLC
Not yet recruiting NCT03971214 - PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung Cancer Phase 1
Active, not recruiting NCT04101357 - Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411 Phase 1/Phase 2
Not yet recruiting NCT04404543 - A Study of SYHA1807 in Subjects With Extensive-Stage Small Cell Lung Cancer Phase 1
Completed NCT04636762 - A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC) Phase 2
Completed NCT03911219 - Impact of eHealth Monitoring on Overall Survival in Patients With Metastatic NSCLC / Extensive-stage SCLC / Advanced TNBC Under First-line Treatment With Atezolizumab Plus Chemotherapy